Maraviroc Waymade (Maraviroc)

Maraviroc is a CCR5 antagonist used in the management of HIV‑1 infection, a viral disease that targets the immune system.

• HIV‑1 infection: Used in combination with other antiretroviral agents to suppress viral replication in patients with CCR5‑tropic virus.
• Treatment‑experienced HIV: Provides an additional option for patients who have developed resistance to other antiretroviral classes.
• Combination antiretroviral therapy: Enhances overall treatment efficacy when paired with nucleoside reverse transcriptase inhibitors and protease inhibitors.

• Maraviroc selectively binds to the CCR5 co‑receptor on CD4+ T‑lymphocytes, blocking the interaction between the receptor and the HIV‑1 envelope glycoprotein gp120. By preventing this binding, the drug inhibits viral entry into the host cell, thereby reducing the ability of the virus to replicate and spread. This mechanism is specific to CCR5‑tropic strains of HIV‑1.

Maraviroc may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate headache reported in clinical studies.
• Nausea: occasional nausea or upset stomach.
• Diarrhea: loose stools or increased bowel movements.
• Fatigue: general tiredness or lack of energy.

Serious or Rare Side Effects

• Liver injury: signs of hepatitis or elevated liver enzymes.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Depression or suicidal thoughts: new or worsening mood changes.
• Cardiovascular events: chest pain, arrhythmia, or hypertension.

When prescribing Maraviroc, clinicians should observe several precautionary measures to ensure patient safety.

• Liver function monitoring: assess hepatic enzymes before and during therapy.
• Cardiovascular assessment: evaluate history of heart disease prior to initiation.
• Mental health screening: monitor for depression or suicidal ideation throughout treatment.
• Hypersensitivity caution: discontinue if signs of severe allergic reaction appear.
• Pregnancy and breastfeeding: use only if potential benefit justifies potential risk, as safety data are limited.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Maraviroc can interact with other medicines, affecting its concentration and therapeutic effect.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin): may increase Maraviroc levels and risk of toxicity.
• Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure and compromise efficacy.
• Certain antiretroviral boosters (e.g., cobicistat): can markedly elevate plasma concentrations.

Moderate Interactions (Monitor Closely)

• Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): may require dose adjustment.
• Anticoagulants (e.g., warfarin): monitor INR for potential changes.
• Other antiretrovirals (e.g., efavirenz): may modestly affect Maraviroc levels.
• Herbal supplements (e.g., St. John’s wort): can induce metabolism and lower drug exposure.